BC Innovations | Oct 27, 2016
Distillery Techniques


TECHNOLOGY: Tool compounds A phenoxybenzamide analog that inhibits PARP-10 could be useful for investigating the role of the enzyme in cancer. In vitro assay screening of a small molecule library yielded a compound that inhibited...
BC Innovations | May 26, 2011
Distillery Therapeutics

Indication: Hematology

This week in therapeutics Hematology Sickle cell disease Not applicable A study in mice suggests pomalidomide could help treat sickle cell disease. In a mouse model of sickle cell disease, pomalidomide led to a similar...
BC Innovations | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Autoimmune disease Autoimmune disease CD28; inducible T cell co-stimulator ligand (ICOSLG; B7-H2) In vitro and cell culture studies suggest inhibiting interactions between B7-H2 and CD28 could help treat autoimmune disease. An...
BC Week In Review | Jan 30, 2006
Clinical News

Hydroxyurea capsules regulatory update

BMY issued a "Dear Healthcare Provider" letter for hydroxyurea capsules to warn about cutaneous vascular toxicites, including vasculitic ulcerations and gangrene, in patients with myeloproliferative disorders during therapy with hydroxyurea, and to inform about the...
BioCentury | Jan 3, 1994

Bristol-Myers calls off Pixykine deal

Bristol-Myers calls off Pixykine deal Pixykine, Immunex Corp. 's peripatetic molecule in development to boost white blood cell and platelet counts following chemotherapy, has found a new home with American Cyanamid Co. IMNX (Seattle) had...
Items per page:
1 - 5 of 5